GLP-1 analogs have been found to be useful for the treatment of patients with Type 2 diabetes (11, 13), and they are currently under investigation as a treatment for nonalcoholic steatohepatitis (NASH), a severe form of nonalcoholic fatty liver disease (NAFLD) (1, 2). Here, GCG is linked to metabolic dysfunction-associated steatotic liver disease.